MedTech 100 roundup: New heights reached again

One week after recording its all-time best performance, the medtech industry once again topped itself, storming even further ahead.

MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — has been on the rise since April began, with last week’s mark of 112.25 (April 16) representing an all-time best, topping the previous high of 110.96 set on Feb. 15.

Just one week later, the index has already bested itself again, reaching 114.58 to end the week on April 23, marking an increase of 2.1% from the previous week.

The rapid improvement continues to shine a light on the strong position the industry has maintained more than a year on from the height of the COVID-19 pandemic’s impact on medtech. The industry has produced a 24.1% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus an 84.4% increase from the mid-pandemic low of 62.13 (March 23, 2020).

The overall markets fared di…

Read more
  • 0

Endeavour Vision closes $375M financing for medtech growth fund

Endeavour Vision announced today that it closed the Endeavour Medtech Growth II fund at $375 million in capital commitments.

Geneva, Switzerland-based Endeavour said in a news release that the fund is set up to support growth-stage medtech and digital health innovations, with new and returning investors supporting EMG II. The fund follows its original growth fund, which launched in 2016 with $275 million.

EMG II adds to Endeavour Vision’s two decades of healthcare investing that has, to date, invested over $500 million in 42 companies, of which 21 have exited through an acquisition or IPO.

The fund has already supported seven companies with investments totalling more than $100 million, with IntelyCare, CeQur, Rapid Micro Biosystems, Sophia Genetics, Nalu Medical, Lumeon and Relievant Medsystems receiving funding from EMG II.

“Governments, citizens and investors are now more aware than ever of our healthcare systems’ strategic importance and …

Read more
  • 0